Beyond Air, Inc. (XAIR) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Beyond Air, Inc. (XAIR) Healthcare & Pipeline Overview

Beyond Air, Inc. is a medical device and biopharmaceutical company focused on developing its proprietary LungFit platform, a nitric oxide generator and delivery system. This platform targets critical respiratory conditions, including persistent pulmonary hypertension of the newborn, viral lung infections, and nontuberculous mycobacteria, positioning the company within the specialized therapeutic gas delivery market.

What Is the Investment Thesis for XAIR?

Beyond Air, Inc. presents an investment thesis centered on the commercialization and pipeline expansion of its proprietary LungFit nitric oxide generator and delivery system. The company's LungFit PH system is already commercialized for persistent pulmonary hypertension of the newborn (PPHN), addressing a critical unmet need in neonatal care. The ongoing development of LungFit PRO for viral lung infections, including COVID-19 and bronchiolitis, and LungFit GO for nontuberculous mycobacteria (NTM) represents significant future growth catalysts. These indications target large patient populations with limited effective treatment options, potentially unlocking substantial market opportunities. The unique mechanism of action of nitric oxide as a therapeutic gas provides a differentiated approach in these areas. Financially, the company currently exhibits a low gross margin of 1.8% and a negative return on equity (ROE) of -240.2%, reflecting its stage as a commercial-stage biopharmaceutical company with significant R&D investments. The debt-to-equity ratio of 284.71 indicates a reliance on debt financing. Future value creation is heavily dependent on successful clinical trials, regulatory approvals, and market adoption of its pipeline products, particularly LungFit PRO and LungFit GO. The company's ability to scale manufacturing, expand commercial reach, and manage its debt will be critical determinants of its long-term viability and shareholder value.

Based on FMP financials and quantitative analysis

XAIR Key Highlights

Market Capitalization: $0.00B, indicating a micro-cap valuation at the time of reporting.

• Gross Margin: 1.8%, reflecting the early commercial stage and cost structure associated with its medical device and biopharmaceutical operations.
• Return on Equity (ROE): -240.2%, indicating significant losses relative to shareholder equity, common for companies in the development and early commercialization phases.
• Debt-to-Equity Ratio: 284.71, suggesting a substantial reliance on debt financing relative to equity to fund operations and development.
• Employee Base: 107 employees, supporting the development and commercialization efforts of the LungFit platform.

Who Are XAIR's Competitors?

XAIR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are XAIR's Key Strengths?

Proprietary LungFit platform technology for nitric oxide generation and delivery.

• Commercialized product (LungFit PH) addressing a critical unmet need in neonatal care.
• Robust pipeline with LungFit PRO and LungFit GO targeting large and high-need respiratory indications.
• Specialized expertise in therapeutic nitric oxide applications.

What Are XAIR's Weaknesses?

Low gross margin (1.8%) indicating high cost of revenue relative to sales.

• Significantly negative Return on Equity (-240.2%) reflecting substantial losses.
• High debt-to-equity ratio (284.71) suggesting reliance on debt financing.
• Small market capitalization ($0.00B) indicating limited access to capital and market liquidity.

What Could Drive XAIR Stock Higher?

XAIR catalyst: Successful completion and positive data readout from pivotal clinical trials for LungFit PRO in viral lung infections.

• Regulatory approval and subsequent commercial launch of LungFit PRO in key markets, expanding the company's addressable patient population.
• Successful completion and positive data readout from pivotal clinical trials for LungFit GO in nontuberculous mycobacteria infections.
• Regulatory approval and subsequent commercial launch of LungFit GO, addressing a high-need chronic respiratory condition.
• Continued commercial expansion and increased market penetration of LungFit PH for persistent pulmonary hypertension of the newborn in existing and new geographic regions.

What Are the Key Risks for XAIR?

Financial-distress signal — its Altman Z-Score of -16.38 sits in the distress zone (elevated bankruptcy risk).

• Significant financial challenges, including a negative Return on Equity of -240.2% and a high debt-to-equity ratio of 284.71%, indicating potential liquidity and solvency concerns.
• Clinical trial failures or unexpected adverse events for LungFit PRO or LungFit GO, which could halt development and diminish future revenue prospects.
• Regulatory hurdles and delays in obtaining marketing approvals for pipeline products, impacting time-to-market and commercialization timelines.
• Intense competitive pressure from larger, more established medical device and biopharmaceutical companies with greater resources and broader product portfolios.
• Challenges in market adoption and reimbursement for new products, even after regulatory approval, limiting commercial success.

What Are the Growth Opportunities for XAIR?

• Expansion into Viral Lung Infections with LungFit PRO: The development of LungFit PRO for community-acquired viral pneumonia, including COVID-19, and bronchiolitis in hospitalized patients represents a substantial growth opportunity. Viral lung infections affect millions globally each year, often leading to severe respiratory distress and hospitalization. The market for effective antiviral and anti-inflammatory respiratory treatments is immense, particularly given the ongoing threat of respiratory pandemics. LungFit PRO's potential to deliver therapeutic nitric oxide, known for its antiviral and anti-inflammatory properties, could position it as a critical intervention. Successful clinical development and regulatory approval for these indications would open access to a large and recurring patient population, significantly expanding Beyond Air's addressable market beyond its current PPHN focus.
• Addressing Nontuberculous Mycobacteria (NTM) with LungFit GO: The development of LungFit GO for nontuberculous mycobacteria (NTM) infections offers another significant growth avenue. NTM infections are chronic, debilitating, and often difficult to treat, particularly in patients with underlying lung diseases like cystic fibrosis or bronchiectasis. The current treatment landscape for NTM is complex, involving prolonged multi-drug regimens with significant side effects and varying efficacy. Nitric oxide's antimicrobial properties against mycobacteria could provide a novel and potentially more effective treatment option. The NTM patient population, while smaller than viral infections, represents a high-need segment with a strong demand for improved therapies, offering a specialized and valuable market for Beyond Air.
• Geographic Market Expansion for LungFit PH: While LungFit PH is commercialized for PPHN, there remains substantial opportunity for geographic expansion beyond its current operational footprint. PPHN is a global condition, and securing regulatory approvals and establishing commercial channels in additional key international markets, such as Europe, Asia, and other developed regions, could significantly increase revenue generation. Expanding market access would involve navigating diverse regulatory environments and establishing robust distribution and sales networks. Successfully entering new territories would leverage the existing clinical data and commercial experience gained from its initial market, broadening the patient reach and revenue base for this critical neonatal therapy.
• Exploration of Additional Therapeutic Indications for Nitric Oxide: The LungFit platform's core technology, a nitric oxide generator and delivery system, holds potential beyond its current targeted indications. Nitric oxide has a wide range of biological effects, including vasodilation, anti-inflammatory, and antimicrobial properties. Investigating and developing the LungFit platform for other respiratory or even systemic conditions where nitric oxide therapy could be beneficial represents a long-term growth opportunity. This could include acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD) exacerbations, or even certain dermatological conditions, diversifying the company's pipeline and reducing reliance on a limited set of indications.
• Strategic Partnerships and Licensing Opportunities: Leveraging the proprietary LungFit platform technology through strategic partnerships or licensing agreements could accelerate market penetration and generate non-dilutive revenue. Collaborating with larger pharmaceutical or medical device companies could provide access to greater financial resources, broader commercial infrastructure, and specialized expertise in specific therapeutic areas or geographic markets. Such partnerships could facilitate the development and commercialization of LungFit PRO and LungFit GO, or even explore new applications of the technology, while mitigating some of the financial and operational risks associated with independent development and market entry.

What Are XAIR's Competitive Advantages?

• Proprietary LungFit platform technology for on-demand nitric oxide generation and precise delivery, differentiating it from traditional compressed gas systems.
• Existing regulatory approvals for LungFit PH in persistent pulmonary hypertension of the newborn, establishing a market presence and barrier to entry.
• Specialized expertise and intellectual property in the application of therapeutic nitric oxide for various respiratory conditions.
• Ongoing clinical development and data generation for pipeline products (LungFit PRO and LungFit GO) targeting significant unmet medical needs, potentially leading to new market exclusivity periods.

What Does XAIR Do?

Beyond Air, Inc., headquartered in Garden City, New York, operates as a specialized commercial medical device and biopharmaceutical company dedicated to addressing critical respiratory conditions. Founded as AIT Therapeutics, Inc., the company underwent a strategic rebranding in June 2019, adopting its current name to better reflect its expansive vision beyond traditional therapeutic approaches. At the core of Beyond Air's innovative portfolio is the LungFit platform, a proprietary nitric oxide generator and delivery system designed to provide precise and controlled therapeutic gas administration. This platform represents a significant technological advancement in the delivery of nitric oxide, a molecule with diverse physiological effects, particularly in the pulmonary vasculature and as an antimicrobial agent. The company's product development pipeline is segmented into distinct applications targeting various patient populations and disease states. LungFit PH is the company's commercially available solution, specifically indicated for the treatment of persistent pulmonary hypertension of the newborn (PPHN). PPHN is a severe condition affecting neonates, characterized by high pulmonary vascular resistance, leading to impaired oxygenation. LungFit PH aims to improve oxygenation and reduce the need for extracorporeal membrane oxygenation (ECMO) in these vulnerable patients. Beyond its commercial offering, Beyond Air is actively advancing two additional applications of its LungFit platform through clinical development. LungFit PRO is being developed to target viral lung infections, encompassing community-acquired viral pneumonia, including severe acute respiratory syndrome coronavirus 2 (COVID-19), as well as bronchiolitis in hospitalized pediatric patients. The potential broad-spectrum antiviral and anti-inflammatory properties of nitric oxide make LungFit PRO a promising candidate for these widespread respiratory illnesses. Furthermore, LungFit GO is under development for the treatment of nontuberculous mycobacteria (NTM), a group of environmental bacteria that can cause chronic, debilitating lung infections, particularly in individuals with pre-existing lung conditions. The ability of nitric oxide to act as a potent antimicrobial agent against various pathogens, including mycobacteria, underpins the therapeutic rationale for LungFit GO. With 107 employees, Beyond Air focuses on bringing these innovative solutions to market to address significant unmet medical needs in respiratory care.

What Products and Services Does XAIR Offer?

• Develops and commercializes the LungFit platform, a proprietary nitric oxide generator and delivery system.
• Offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn (PPHN).
• Is developing LungFit PRO for the treatment of viral lung infections, including community-acquired viral pneumonia and COVID-19.
• Is developing LungFit PRO for bronchiolitis in hospitalized patients.
• Is developing LungFit GO for the treatment of nontuberculous mycobacteria (NTM) infections.
• Focuses on delivering therapeutic nitric oxide for various critical respiratory conditions.
• Operates as a commercial medical device and biopharmaceutical company.
• Headquartered in Garden City, New York, with 107 employees.

How Does XAIR Make Money?

• Sells or leases its LungFit PH nitric oxide generator and delivery system to hospitals and healthcare providers, primarily neonatal intensive care units.
• Generates revenue from the sale of consumables and accessories required for the ongoing operation of the LungFit PH system.
• Invests significantly in research and development for pipeline products, LungFit PRO and LungFit GO, with the aim of future commercialization and revenue generation.
• Seeks regulatory approvals for new therapeutic indications and geographic markets to expand its addressable market and diversify revenue streams.

What Industry Does XAIR Operate In?

Beyond Air, Inc. operates at the intersection of the medical device and biopharmaceutical industries, specifically within the niche market of therapeutic gas delivery systems for respiratory conditions. The broader medical device market is characterized by innovation, stringent regulatory oversight, and a focus on improving patient outcomes through advanced technologies. Within this context, the therapeutic gas segment, particularly for nitric oxide, addresses critical needs in pulmonary care. Market trends indicate a growing demand for non-invasive and targeted therapies for respiratory infections and pulmonary vascular diseases. Beyond Air's LungFit platform positions it as a developer of proprietary nitric oxide generation and delivery technology, differentiating it from traditional compressed gas cylinder systems. The competitive landscape includes established medical gas suppliers and other companies developing novel respiratory therapies. Beyond Air's strategy involves penetrating markets with significant unmet needs, such as PPHN, and expanding into broader indications like viral pneumonia and NTM, where its technology could offer a distinct advantage over existing or emerging treatments.

Who Are XAIR's Key Customers?

• Hospitals and neonatal intensive care units (NICUs) that utilize LungFit PH for treating newborns with PPHN.
• Healthcare systems and clinics that will treat patients with viral lung infections, such as pneumonia and bronchiolitis, upon LungFit PRO's potential commercialization.
• Specialized clinics, pulmonologists, and infectious disease specialists managing nontuberculous mycobacteria infections, for whom LungFit GO is being developed.
• Ultimately, patients suffering from severe respiratory conditions who can benefit from therapeutic nitric oxide delivery.

Company Profile

Beyond Air, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Garden City, US. The company is led by CEO Robert Goodman. XAIR has traded publicly since 2018.

Beyond Air, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -16.38 places it in the distress zone, a signal of elevated financial risk.

XAIR Valuation & Market Position

With a $3.66M market cap, Beyond Air, Inc. sits in the micro-cap segment of the market. Relative to its peer group, XAIR's quantitative score of 17/100 is below the peer average of 65/100.

Quarterly Financial Performance: Beyond Air, Inc.

Revenue for Beyond Air, Inc. came in at $1.8M during Q2 2026, a 7.3% contraction versus the preceding quarter. The company recorded a net loss of $7.9M, with diluted EPS of $-11.00. Revenue has contracted over three consecutive quarters, which investors in this micro-cap Healthcare stock should monitor closely. Across the four most recent quarters, XAIR averaged $-13.40 in diluted EPS.

Beyond Air, Inc. has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 25.7% above estimates on average.

Wall Street analysts project Beyond Air, Inc. revenue of about $8.1M for fiscal 2026, with EPS near $-75.47.

XAIR Financials

XAIR Latest News

XAIR Analyst Consensus

XAIR MoonshotScore

Common Questions About XAIR (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources